Avaliação in vitro de caracteristicas probióticas do enterococcus faecium CRL 183 e do Lactobacillus helveticus ssp jugurti 416

Pós-graduação em Alimentos e Nutrição - FCFAR

O emprego da metodologia de superfície de resposta no desenvolvimento de um novo produto simbiótico, fermentado com Enterococcus faecium CRL 183 e Lactobacillus helveticus ssp jugurti 416, à base de extratos aquosos de soja e de Yacon (Smallanthus sonchifolius)

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Probiotic Enterococcus faecium CRL 183 inhibit chemically induced colon cancer in male Wistar rats

Several animal studies have shown that supplementation with specific strains of lactic acid bacteria could prevent the establishment, growth, and metastasis of transplantable and chemically induced tumors. The goal of this study was to determine the effect of Enterococcus faecium CRL 183 on the incidence of colorectal tumors induced experimentally by dimethylhydrazine (DMH). We used thirty 4-week old male Wistar rat. The animals belonging to the DMH groups were injected s.c 20 mg/kg body weight of 1,2 dimethylhydrazine and 1 mM EDTA (pH 6.5), in a weekly dose, for 14 weeks. Three groups were used: (1) Control (not initiated); (2) Initiated with DMH; (3) Initiated with DMH + intake of E. faecium CRL 183. At the end of the 42nd week, all the animals were euthanized; the colons were removed and analyzed histologically. All the groups were compared histologically and IL-4, IFN-gamma and TNF-alpha cytokines. The control group did not develop pre-neoplastic lesions. The E. faecium CRL 183-DMH group showed a 50% inhibition in incidence in average number of tumors (P < 0.001), reduced the formation of ACF (P < 0.001), the lowest number of adenocarcinoma being found in this group (P < 0.001) and enhanced the immune response by increasing IL-4, IFN-gamma and TNF-alpha (P < 0.001) when compared with the DMH group.

Demonstration of the cellular viability and safety of Enterococcus faecium CRL 183 in long-term experiments

Enterococcus faecium CRL 183, a strain isolated from NSLAB cheese starter, has been the focus of much research on its potential probiotic capacity, although its survival through the gastrointestinal tract has not been demonstrated so far. In order to determine the capacity of E. faecium CRL 183 to survive such conditions, this strain was administered daily to rats for 30 weeks. The experimental animals were divided into Group I: those that did not receive E. faecium, Group II: those that received a pure culture of E. faecium CRL 183 and Group III: animals that received E. faecium CRL 183 in the form of a fermented soy-based product. Faecal samples were collected at the beginning and at the 50%, 75% and 100% stages of the experimental period. Isolation and counts of Enterococcus were carried out on KF selective media. To distinguish the various Enterococcus species in the faeces, biochemical (API Strep 20) and molecular (PCR) tests were performed. Initially, E. faecium was absent from the intestinal flora of the rats; however, after 15 weeks of administration, E. faecium could be recovered from the faeces of Groups II and III, demonstrating that E. faecium CRL 183 was able to survive gastrointestinal transit under the study conditions. This is further evidence of the probiotic qualities of this strain. The safety of the strain was also investigated with regard to body weight and serum biochemical analysis.

Avaliação do simbiótico fermentado com Enterococcus faecium CRL 183 e Lactobacillus helveticus ssp jugurti 416, à base de extratos aquosos de soja e de yacon (Smallanthus sonchifolius) no controle do desenvolvimento do Diabetes Mellitus

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Efeito de uma bebida probiótica (Enterococcus faecium CRL 183 e Bifidobacterium longum ATCC 15707) à base de extrato aquoso de soja no desenvolvimento de colite quimicamente induzida em ratos

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Avaliação da adição da Lactobacillus acidophilus CRL 1014 e Enterococcus faecium CRL 183 sobre a microbiota intestinal em Simulador do Ecossistema Microbiano Humano (SEMH)

Os micro-organismos probióticos são utilizados em vários produtos alimentícios ou em suplementos alimentares. Simuladores intestinais representam uma opção de realização de estudos com a microbiota intestinal. O simulador do ecossistema microbiano humano (SEMH) consiste em uma sucessão de cinco reatores conectados que representam as diferentes partes do trato gastrointestinal humano com seus respectivos valores de pH, tempo de residência e capacidade volumétrica. O SEMH foi utilizado para estudar o efeito do Enterococcus faecium CRL 183 e do Lactobacillus acidophilus CRL 1014 sobre a microbiota intestinal nativa. Inicialmente, o inóculo preparado com fezes humanas foi introduzido nos três reatores, responsáveis por simular o cólon ascendente, transverso e descendente. Após duas semanas de estabilização foi adicionado, diariamente, durante quatro semanas, E. faecium CRL 183 e L. acidophilus CRL 1014 contendo 108 UFC/mL nos três compartimentos que simulam o cólon ascendente, transverso e descendente. Após as quatro semanas de tratamento o sistema permaneceu durante duas semanas sem adição de probióticos. Durante todo o experimento, foi realizado semanalmente a composição da microbiota intestinal baseada na enumeração de bactérias aeróbias e anaeróbias totais, Enterococcus spp., Lactobacillus spp., Bifidobacterium spp., Enterobactérias e Clostridium spp. Semanalmente, também, foram realizadas análises de ácidos graxos de cadeia curta (acetato, butirato e propionato) e amônia. Através da análise microbiológica observou-se alterações significativas na composição da microbiota do SEMH no decorrer do período do experimento. Alterações significativas também foram observadas na concentração de amônia e de AGCC, podendo assim observar a influência da inoculação de probióticos na microbiota nativa e os metabólitos produzidos por ela

Efeito da adição de inulina no crescimento, resistência gastrintestinal e capacidade de remoção de colesterol de Lactobacillus helveticus 416 e Enterococcus faecium CRL 183

O objetivo do presente estudo foi verificar o efeito da adição de um prebiótico nas características de crescimento, resistência às condições do trato gastrintestinal e remoção de colesterol in vitro, das cepas de Enterococcus faecium CRL183 e Lactobacillus helveticus 416. A fonte de prebiótico foi composta por Inulina GR – Orafti, sendo testadas as seguintes concentrações: 1,0%, 2,0%, 3,0%; 4,0%; 5,0% e 6,0% p/v). Para a avaliação da resistência às condições do trato gastrintestinal, os microrganismos foram colocados em contato com um fluido gástrico simulado por 2 horas (9g/L de NaCl, 3g/L de pepsina, pH 1,8) e com um fluido intestinal simulado por 3 horas (0,9g/L de pancreatina, 12,5g/L de bicarbonato de sódio e 6,0 g/L de Oxgall). Após o período de contato com os fluidos, foram realizadas diluições seriais e plaqueamento em meios específicos. No estudo de redução de colesterol, meios de cultura contendo inulina e colesterol (1%) foram inoculados com as cepas probióticas e incubados em anaerobiose a 37°C/24h. A capacidade de redução do colesterol foi determinada pela diferença entre a concentração de colesterol adicionada ao meio de cultura e a de colesterol residual. Os resultados foram submetidos à análise de variância e teste de médias de Tukey (p≤0,05). A adição de inulina não resultou em alteração no ciclo logarítmico de crescimento dos microrganismos. Porém, quando os dados foram submetidos à análise estatística, constatou-se que a adição de 1% a 4% de inulina inibiu o crescimento de Lactobacillus helveticus 416, sendo que para as concentrações de 5% a 6% estas alterações não foram perceptíveis. A cepa de Enterococcus faecium CRL 183 apresentou crescimento superior na presença de 2% e 4% de inulina. Após o contato com o fluido gástrico simulado, observou-se redução de 1 ciclo logarítmico no crescimento da cepa... (Resumo completo, clicar acesso eletrônico abaixo)

Fermentation by gut microbiota cultured in a simulator of the human intestinal microbial ecosystem is improved probiotic Enterococcus faecium CRL 183

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Influência do consumo de Iogurte de soja fermentado com Enterococcus faecium na microbiota intestinal de animais e humanos

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Intake of isoflavone-supplemented soy yogurt fermented with Enterococcus faecium lowers serum total cholesterol and non-HDL cholesterol of hypercholesterolemic rats

The aim of this study was to obtain an isoflavone-supplemented soy yogurt, fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus ssp jugurti, with suitable sensory properties and to assess the effects of the final product on blood lipids in hypercholesterolemic rats. Four isoflavone supplementation procedures were tested, in which the isoflavone was added at these stages: (1) before heat-treatment; (2) after heating and before fermentation; (3) after fermentation and (4) in the okara (by-product of soy milk) flour stirred into the fermented product when consumed. The products were subjected to a test of sensory acceptability. To assess their potential hypocholesterolemic properties in vivo, four groups of rats were used: control (C), hypercholesterolemic (H), hypercholesterolemic plus fermented product (HF) and hypercholesterolemic plus isoflavone-supplemented fermented product (HFI). Hypercholesterolemia was induced in rats of groups H, HF and HFI by feeding them on a commercial rat chow to which cholesterol and cholic acid had been added. Total, HDL and non-HDL cholesterol and triglycerides were measured in the blood of the rats. No significant sensorial differences were detected among the samples of soy yogurt supplemented with isoflavones at various processing stages. Rats fed a fermented soy product enriched with isoflavones (HFI group) had significantly (P < 0.05) less serum total cholesterol (15.5%) compared with rats fed a hypercholesterolemic diet (H group). Non-HDL cholesterol was less (P < 0.05) in rats fed a fermented soy product enriched or not with isoflavones (27.4 and 23.2%) compared to H group. The HDL-C and triglyceride concentrations did not differ significantly among the groups. It was possible to obtain an isoflavone-supplemented soy yogurt with satisfactory sensory characteristics. The resulting supplemented soy yogurt was capable of producing a lipid-lowering effect in hypercholesterolemic rats, relative to the animals that did not consume this product.

Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model

Background: Previous work showed that daily ingestion of an aqueous soy extract fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus 416, supplemented or not with isoflavones, reduced the total cholesterol and non-HDL-cholesterol levels, increased the high-density lipoprotein (HDL) concentration and inhibited the raising of autoantibody against oxidized low-density lipoprotein (ox-LDL Ab) and the development of atherosclerotic lesions. Objective: The aim of this study was to characterize the fecal microbiota in order to investigate the possible correlation between fecal microbiota, serum lipid parameters and atherosclerotic lesion development in rabbits with induced hypercholesterolemia, that ingested the aqueous soy extract fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus 416. Methods: The rabbits were randomly allocated to five experimental groups (n = 6): control (C), hypercholesterolemic (H), hypercholesterolemic plus unfermented soy product (HUF), hypercholesterolemic plus fermented soy product (HF) and hypercholesterolemic plus isoflavone-supplemented fermented soy product (HIF). Lipid parameters and microbiota composition were analyzed on days 0 and 60 of the treatment and the atherosclerotic lesions were quantified at the end of the experiment. The fecal microbiota was characterized by enumerating the Lactobacillus spp., Bifidobacterium spp., Enterococcus spp., Enterobacteria and Clostridium spp. populations. Results: After 60 days of the experiment, intake of the probiotic soy product was correlated with significant increases (P < 0.05) on Lactobacillus spp., Bifidobacterium spp. and Enterococcus spp. and a decrease in the Enterobacteria population. A strong correlation was observed between microbiota composition and lipid profile. Populations of Enterococcus spp., Lactobacillus spp. and Bifidobacterium spp. were negatively correlated with total cholesterol, non-HDL-cholesterol, autoantibodies against oxidized LDL (ox-LDL Ab) and lesion size. HDL-C levels were positively correlated with Lactobacillus spp., Bifidobacterium spp., and Enterococcus spp. populations. Conclusion: In conclusion, daily ingestion of the probiotic soy product, supplemented or not with isoflavones, may contribute to a beneficial balance of the fecal microbiota and this modulation is associated with an improved cholesterol profile and inhibition of atherosclerotic lesion development.

Effects of isoflavone-supplemented soy yogurt on lipid parameters and atherosclerosis development in hypercholesterolemic rabbits: a randomized double-blind study

Background: There is increasing interest in natural treatments to control dyslipidemia and reduce the risk of cardiovascular disease. Previous studies have demonstrated the beneficial effects of soy yogurt fermented with Enterococcus faecium CRL 183 and of dietary isoflavones on the lipid profile. The purpose of the present study was to investigate the effects of isoflavone-supplemented soy yogurt, fermented with E. faecium CRL183, on lipid parameters and atherosclerosis development in rabbits with induced hypercholesterolemia. Methods: Forty-eight rabbits were randomly assigned to eight groups fed on the following diets for 60 days: C - control; IY - isoflavone-supplemented soy yogurt; H - hypercholesterolemic (1.0% cholesterol wt/wt diet); HY - hypercholesterolemic plus soy yogurt; HIY - hypercholesterolemic plus isoflavone-supplemented soy yogurt; HP - hypercholesterolemic plus placebo; HI hypercholesterolemic plus isoflavone and HE - hypercholesterolemic plus pure culture of E. faecium CRL 183. Serum lipids and autoantibodies against oxLDL (oxLDL Ab) were analyzed on days 0, 30 and 60 of the treatment and the atherosclerotic lesions were quantified at the end of the experiment. Results: Soy yogurt, soy yogurt supplemented with isoflavones and placebo promoted significant reductions in total cholesterol level (38.1%, 27.0% and 26.6%, respectively). Significant increases in serum HDL-C concentration relative to group H were detected in animals that ingested soy yogurt, with or without the isoflavone supplement (55.2%), E. faecium culture (43.3%) or placebo (35.8%). Intake of soy yogurt and soy yogurt supplemented with isoflavones prevented the rise of oxLDL Ab during the study period. The extent of atherosclerosis in the thoracic and abdominal aortas was reduced in the HIY, HY and HP groups. However, when the whole aorta was analyzed, animals treated with soy yogurt supplemented with isoflavones exhibited the greatest reduction (51.4%, P < 0.05) in atherosclerotic lesion area, compared to group H. Conclusion: Soy yogurt could be consumed as an alternative means of reducing the risk of cardiovascular disease by improving the lipid profile and inhibiting oxLDL Ab formation. Our findings also suggest that isoflavone supplementation may enhance the antiatherosclerotic effect of soy yogurt.

Desenvolvimento de pastilha potencialmente probiótica

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Effect of ingestion of soy yogurt on intestinal parameters of rats fed on a beef-based animal diet

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)